北交所再融资

Search documents
北交所公司再融资新进展: 锦波生物20亿元定增获受理
Zhong Guo Zheng Quan Bao· 2025-09-21 20:17
Group 1 - Jinbo Bio has announced a private placement of shares, which has been accepted by the Beijing Stock Exchange, aiming to raise up to 2 billion yuan by issuing no more than 7.1757 million shares [1][2] - The strategic investor for this placement is Yangshengtang, which will acquire shares at a price of 278.72 yuan per share, resulting in a 6.24% ownership stake in Jinbo Bio post-issuance [2] - The funds raised will be allocated to the development of a humanized collagen FAST database and product development platform, with 1.15 billion yuan dedicated to this project, enhancing the company's competitiveness in various medical fields [2][3] Group 2 - The private placement represents the largest scale of financing through a private placement on the Beijing Stock Exchange this year [2] - Jinbo Bio's collaboration with Yangshengtang is expected to bring advanced technological resources, enhancing core competitiveness and innovation capabilities, as well as improving market channels and brand resources [3] - Meanwhile, Wantong Hydraulic has received approval for a private convertible bond issuance, aiming to raise up to 150 million yuan to support its liquidity needs [4][5]
定向可转债发行加速,北证再融资的新方向?
北证三板研习社· 2025-05-20 09:50
今年2月,优机股份(833943.BJ)公告《发行定向可转债的募集说明书》, 开创了北交所定向可转债的 先河 。4月1日,北交所从合法规范经营、持续经营能力、投资者保护措施、预沟通机制等八个维度明 确了北交所上市公司再融资监管导向,表示"支持上市公司通过定向发行可转债融资",随即万通液压 (830839.BJ)、威博液压(871245.BJ)两家公司在月内启动了发行定向可转债的工作, 似乎在为北交 债券要素方面,3只北交所可转债的初始转股价格更高,为20个交易日均价的120%(沪深一般就是均价 或者向下打折),更高的转股价格意味着持有者的转股门槛更高,转股套利越难, 可转债的"债性"更强 。由于北交所公司股本规模相对较小,通过设置较高的转股价格,可以 延缓转股进程,避免短期内大量 转股导致的股权稀释 (以及转股套利者打压股价),维持现有股东的控制权。 此外,优机股份和威博液压的回售门槛与沪深相同(初始转股价的70%),赎回门槛(140%)则高于沪 深(130%);而万通液压的赎回门槛低于沪深、回售门槛还远低于沪深(认购方盘古智能的让利,也 更能说明其对公司前景的看好)。赎回旨在股价过高时维护公司利益,回售则是 ...